Saturday, April 30, 2016

Euro Pacific upgrades Sophiris Bio to buy

Euro Pacific upgrades Sophiris Bio to buy

November 11, 2015 by · Leave a Comment 

Tweet Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in benign prostatic hyperplasia (BPH). Shares of Sophiris closed at $2.90 on Tuesday after jumping $2.04 on the […]

biOasis to file IND for HER2+ brain cancer treatment in 2016

biOasis to file IND for HER2+ brain cancer treatment in 2016

June 23, 2015 by · Leave a Comment 

Tweet biOasis (OTCQX:BIOAF; TSX-V:BTI) hopes to file an Investigational New Drug application with the FDA next year to begin human testing of its Transcend platform against HER2 positive brain tumors, which result from HER2+ breast cancer metastasizing to the brain. “Given the significant unmet medical need of this condition, we are in discussions for a […]

Byron Capital ups Cipher price target

Byron Capital ups Cipher price target

May 6, 2013 by · Leave a Comment 

Tweet Byron Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $6.25 from $5.25, after the company posted record results for the first quarter. The stock closed at $3.80 on Friday. “Our key takeaway is the Absorica launch is outperforming even our optimistic expectations,” writes analyst Doug Loe. On Absorica’s […]

Byron Capital lifts Transition price target

Byron Capital lifts Transition price target

May 1, 2013 by · Leave a Comment 

Tweet Bryon Capital Markets has raised its price target on “speculative buy-rated” Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) to $5.25 from $3.25 after the company reported positive top-line data from its Phase 1/2 trial with 60 Type 2 diabetic patients, testing Eli Lilly’s GLP-1-glucagon dual agonist peptide drug TT-401 as a once-weekly blood glucose-lowering and weight loss […]

OncoGenex’s OGX-427 drug gaining investor attention

OncoGenex’s OGX-427 drug gaining investor attention

March 26, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=3q82Rl_y8Rc’]

Tweet Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second generation antisense drug, OGX-427. “We have data in bladder and prostate cancer with OGX-427 that, we believe, indicates clinical activity,” co-founder, president and CEO, Scott Cormack, says in […]

Bryon Capital ups Cipher price target to $5.25

Bryon Capital ups Cipher price target to $5.25

March 1, 2013 by · Leave a Comment 

Tweet Bryon Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $5.25 from $4.50 after the drug developer posted record results for 2012. The stock closed at $2.90, up 45 cents, or 18% on Friday. Analyst Doug Loe said his target is still based on 15 times estimated 2015 results, […]

Byron Capital ups Transition Therapeutics to buy

Byron Capital ups Transition Therapeutics to buy

February 12, 2013 by · Leave a Comment 

Tweet Byron Capital has upgraded Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to “buy” from “hold” and raised its price target to $3.25 from $2.25 after the company reported fiscal third quarter results and updated its pipeline activities. The stock was quoted at $2.20 on Tuesday morning. Current activities include two sizable Phase 2 CNS trials testing Transition’s […]

Bryon Capital ups Novadaq to buy

Bryon Capital ups Novadaq to buy

February 7, 2013 by · Leave a Comment 

Tweet Byron Capital Markets has upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “buy” from “hold” and raised its price target to $15 from $12, after the medical imaging company reported strong fourth quarter results this morning. The stock was changing hands at $9.27 Thursday afternoon. “We maintain our positive view on pace of SPY adoption in […]

Byron Capital starts Cipher at buy

Byron Capital starts Cipher at buy

February 4, 2013 by · Leave a Comment 

Tweet Byron Capital Markets has upped Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to a “buy” rating from an “idea of interest” last year with a price target of $4.50, after introducing formal EBITDA forecasts and a valuation for Cipher’s approved product portfolio. The stock closed at $2.70 on Friday. Analyst Doug Loe writes that Cipher’s “risk profile […]

Transition partner begins Phase 2 bipolar trial

Transition partner begins Phase 2 bipolar trial

August 31, 2012 by · Leave a Comment 

Tweet Transition Therapeutics’ (TSX:TTH; NASDAQ:TTHI) licensing partner, Elan Corp., has begun a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes. As the first patient has been dosed in this study, Transition […]

Next Page »

Email Newsletters with Constant Contact
Google+